A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Taladegib (Primary)
- Indications Advanced breast cancer; Basal cell cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly; Ignyta
- 26 Feb 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.